Cargando…
Maslinic Acid Enhances Docetaxel Response in Human Docetaxel-Resistant Triple Negative Breast Carcinoma MDA-MB-231 Cells via Regulating MELK-FoxM1-ABCB1 Signaling Cascade
Docetaxel (DOC) is the most important chemotherapeutic drug for the treatment of triple negative breast cancer (TNBC); however, acquired drug resistance upon the long-term treatment limits its therapeutic effect. Maslinic acid (MA), a natural triterpene from Olea europaea L., attracts increasing int...
Autores principales: | Wang, Ke, Zhu, Xue, Yin, Yongxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295941/ https://www.ncbi.nlm.nih.gov/pubmed/32581798 http://dx.doi.org/10.3389/fphar.2020.00835 |
Ejemplares similares
-
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells
por: Tam, Stanton, et al.
Publicado: (2022) -
Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7
por: Park, Sang O, et al.
Publicado: (2015) -
Docetaxel-loaded PLGA nanoparticles to increase pharmacological sensitivity in MDA-MB-231 and MCF-7 breast cancer cells
por: Tran, Phuong, et al.
Publicado: (2021) -
PRIMA-1(MET) Does Not Restore Vitamin
D Sensitivity to MDA-MB-231 and MDA-MB-468 Triple-Negative Breast
Cancer Cells
por: Kotob, Shadi N., et al.
Publicado: (2023) -
Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways
por: Maharjan, Sushma, et al.
Publicado: (2023)